Olema Oncology to Present at Two Upcoming Investor Conferences

SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that management will participate in two upcoming investor conferences in November.

Details for the company’s participation are as follows:

• Event: Jefferies London Healthcare ConferenceDate: Tuesday, November 16, 2021Time: 5:00 p.m. GMT (12:00 p.m. ET / 9:00 a.m. PT)Format: Live Fireside Chat
• Event: 4th Annual Evercore ISI HealthCONx ConferenceDate: Tuesday, November 30, 2021Time: 11:45 a.m. ET (8:45 a.m. PT) Format: Live Fireside Chat

Live webcasts of these presentations may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be archived for 14 days.

About Olema OncologyOlema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is based in San Francisco and has operations in Cambridge, Massachusetts.

Contact:Eva StroynowskiVice President, Communications and Investor Relations[email protected]

You May Also Be Interested In

• Steelworkers back Canada holding the line on trade, call for a stronger response to protect Canadian jobs and industry
• ComEd Sending More Than 60 Employees to Assist NIPSCO with Restoration Work
• 2026’s Top Window Covering Trends, and the Sister-Owned Store Carrying Them All